MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
This article was originally published in The Gray Sheet
Executive Summary
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2
You may also be interested in...
Combination Product Submissions Rose 10% In FY 2005 – FDA
FDA received 275 applications for combination products in fiscal year 2005, a 10% increase over the prior year, according to a May 29 report to Congress
Combination Product Submissions Rose 10% In FY 2005 – FDA
FDA received 275 applications for combination products in fiscal year 2005, a 10% increase over the prior year, according to a May 29 report to Congress
CBER Review “Paradigm Shift” Credited With Improved Cycle/Review Stats
The Center for Biologics Evaluation & Research is working to identify problems with premarket applications earlier so they can be resolved in the first cycle of review, according to Robert Yetter, CBER associate director for review management